The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced Anemia
Ralph V. Boccia(Center for Cancer and Blood Disorders), Lodovico Balducci(Moffitt Cancer Center), Tom Lillie, Dianne Tomita
Cited by 16
Related Papers
Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score
|Cancer|2011|1.1k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
|European Journal of Cancer|1993|545
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425